Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events

Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events
复制标题

KYOTO HEART 研究的基本原理和设计:缬沙坦对心血管事件高风险未控制的高血压患者发病率和死亡率的影响

DOI:
10.1038/jhh.2008.116
复制
发表时间:
2009
影响因子:
2.7
通讯作者:
H. Matsubara
H. Matsubara
中科院分区:
医学4区
文献类型:
--
作者:
T. Sawada;Tomosaburo Takahashi;Hiroyuki Yamada;B. Dahlöf;H. Matsubara

文献摘要

参考文献

被引文献

相似文献

目前仍有待确定西方国家在心血管疾病中阻断肾素-血管紧张素系统的证据是否可以直接应用于东亚人种,包括日本人群作为长期策略。京都HEART研究(KHS)旨在研究缬沙坦与常规抗高血压治疗相比,对血压不受控制且心血管风险高的日本高血压患者心血管发病率和死亡率的附加效应。超过3000例高血压不受控制的高风险日本患者随机接受缬沙坦或传统非血管紧张素受体阻滞剂治疗,随访期至少为3年。主要终点是确定的心血管或心血管事件的复合终点。次要终点包括所有死亡原因、心功能恶化、新发心律失常或糖尿病或心律失常恶化。KHS将为高危高血压患者的血压管理提供新的证据。
It remains to be determined whether the evidence in Western countries for blockade of the renin–angiotensin System in cardiovascular diseases could be directly applied to East Asian races including the Japanese population as a long-term strategy. The KYOTO HEART Study (KHS) is designed to investigate the add-on effect of valsartan versus conventional anti-hypertensive treatment on cardiovascular morbidity and mortality in Japanese hypertensive patients with uncontrolled blood pressure and with high cardiovascular risk. Over 3000 high-risk Japanese patients with uncontrolled hypertension were randomised to receive either additional treatment with valsartan or conventional non-angiotensin receptor blocker therapies, and the follow-up period will be at least 3 years. The primary end point is a composite of defined cardio-or cerebro-vascular events. Secondary end points include all causes of mortality, worsening of cardiac function, new onset or worsening of arrhythmias or diabetes mellitus. The KHS will provide new evidence for the management of blood pressure in hypertensive patients with high risk.
替米沙坦替代 2 型糖尿病高血压患者的缬沙坦和坎地沙坦:代谢和抗动脉粥样硬化后果。
DOI: --
发表时间: 2005
期刊: Diabetes Care 28
影响因子: --
作者:
Miura Y;Yamamoto N;Tsunekawa S;Taguchi S;Eguchi Y;Ozaki N;Oiso Y
通讯作者: Oiso Y
DOI: 10.1016/s0140-6736(07)60669-2
发表时间: 2007-04-01
期刊: LANCET
影响因子: 168.9
作者:
Mochizuki, Seibu;Dahloef, Bjorn;Tajima, Naoko
通讯作者: Tajima, Naoko